Tevogen Launches Generics Division to Tackle Drug Affordability and Boost U.S. Manufacturing

Tevogen Bio Holdings Inc. (Nasdaq: TVGN) has announced the launch of Tevogen Generics, a new initiative aimed at addressing pharmaceutical affordability in the U.S., especially in light of renewed national conversations around drug costs and recent tariff-related remarks from former President Donald Trump.

The company has appointed Sadiq Khan, MBA—its current Chief Commercial Officer—as Interim Head of Tevogen Generics. With decades of experience in global pharma operations and strategic alliances, Khan is set to lead this new initiative focused on bolstering domestic manufacturing of unbranded medications and active pharmaceutical ingredients (APIs).

“This initiative seeks to expedite the domestic manufacturing of unbranded pharmaceuticals and APIs, thereby enhancing national self-reliance in the supply of vital, life-saving treatments,” said Khan.

Tevogen Generics becomes the third core pillar of the company’s growing portfolio, alongside:

• Tevogen Bio – focused on precision, off-the-shelf T cell therapies in immunotherapy.

• Tevogen.AI – using artificial intelligence to accelerate drug discovery and optimize healthcare systems.

• Tevogen Generics – dedicated to making essential, high-quality medicines more accessible and affordable.